Lately, the very first guidelines that are available for the chronic fungal lung illnesses for the doctors and laboratories were published by the ERS (European Respiratory Society) and ESCMID (European Society of Clinical Microbiology). These guidelines that are published in the European Respiratory Journal, these guidelines elaborate the most important features of this specific disease, and it also provides highly comprehensive treatment recommendations. The CPA (Chronic Pulmonary Aspergillosis) is an insidious and subtle problem in the patients who already have damaged lungs. This condition has killed almost 80 percent of the sufferers in a time period of five years unless the condition is diagnosed and treated using long term anti-fungals. All through Europe, around 240,000 people are estimated to have CPA and the number accounts to 3 million across the world.
Major enhancements in the understanding of this debilitating and fatal disorder have resulted from the research that has been undertaken in Europe, Japan and India over the last decade. However, no therapies are approved by the EMA (European Medicines Agency) for treatment. However, a few diagnostic tests as well as therapies have been compared with one another. In most parts of the world, even the basic tests that are needed are not available.
As per Professor David Denning at the University of Manchester heading the CPA guidelines group, the UK National Health Service has identified the challenges that are posed by the patients in setting up the National Aspergillosis Center and also its associated laboratory, Mycology Reference Center in the year 2009. The experience is gained by seeing hundreds of patients who have contributed to the quality of care. However, more research and the latest oral antifungal drugs are needed to reduce the market disability that is caused by CPA.
Dr. Marc Miravitlles, the ERS guidelines director, they welcome the publication of these guidelines that provides key insights into the major features of the disease and treatment recommendations. By establishing the expert consensus related to the topic, they aim to enhance the early diagnosis of CPA and also increase the recognition of this condition to improve the outcomes for patients. The guidelines are nothing but a product that is a result of the two-year collaboration between the ERS and ESCMID. The latter is developing wider guidelines right now for invasive aspergillosis, and the same will be published in the course of time. The chairman of EFISG, Andrew Ullmann claims that these guidelines on the chronic pulmonary aspergillosis are a truly interdisciplinary collaboration that is prepared and published for the colleagues available on a group of complex diseases that are very tough to manage.